IL276089B2 - Methods for colon cancer detection and treatment monitoring - Google Patents

Methods for colon cancer detection and treatment monitoring

Info

Publication number
IL276089B2
IL276089B2 IL276089A IL27608920A IL276089B2 IL 276089 B2 IL276089 B2 IL 276089B2 IL 276089 A IL276089 A IL 276089A IL 27608920 A IL27608920 A IL 27608920A IL 276089 B2 IL276089 B2 IL 276089B2
Authority
IL
Israel
Prior art keywords
expression level
score
subject
stoml2
adrm1
Prior art date
Application number
IL276089A
Other languages
English (en)
Hebrew (he)
Other versions
IL276089B1 (en
IL276089A (en
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of IL276089A publication Critical patent/IL276089A/en
Publication of IL276089B1 publication Critical patent/IL276089B1/en
Publication of IL276089B2 publication Critical patent/IL276089B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
IL276089A 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring IL276089B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862620015P 2018-01-22 2018-01-22
PCT/US2019/014490 WO2019144099A1 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Publications (3)

Publication Number Publication Date
IL276089A IL276089A (en) 2020-08-31
IL276089B1 IL276089B1 (en) 2024-03-01
IL276089B2 true IL276089B2 (en) 2024-07-01

Family

ID=65279827

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276089A IL276089B2 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Country Status (14)

Country Link
US (3) US11414707B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743534B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297770B2 (cg-RX-API-DMAC7.html)
CN (1) CN112004945B (cg-RX-API-DMAC7.html)
AU (1) AU2019209436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014737A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3743534T3 (cg-RX-API-DMAC7.html)
ES (1) ES2917629T3 (cg-RX-API-DMAC7.html)
IL (1) IL276089B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007771A (cg-RX-API-DMAC7.html)
PL (1) PL3743534T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202006974WA (cg-RX-API-DMAC7.html)
WO (1) WO2019144099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3743534T3 (da) 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
US11809379B2 (en) * 2019-11-19 2023-11-07 International Business Machines Corporation Storage tiering for deduplicated storage environments
CN111157745A (zh) * 2020-01-17 2020-05-15 上海交通大学 人snrpa蛋白在肺癌复发或转移监测中的用途
CN115475247B (zh) * 2021-06-16 2024-02-20 厦门大学 β2-微球蛋白或其抑制剂的制药用途
CN113921079B (zh) * 2021-12-06 2022-03-18 四川省肿瘤医院 基于免疫相关基因的msi预测模型构建方法
CN121137146B (zh) * 2025-07-28 2026-04-07 首钢医院有限公司 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169077A1 (en) * 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
EP2169078A1 (en) * 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
KR101051435B1 (ko) * 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101073875B1 (ko) * 2008-11-28 2011-10-14 한국생명공학연구원 대장암 진단 마커 및 이를 이용한 대장암 진단방법
EP2425020A4 (en) 2009-05-01 2016-04-20 Genomic Health Inc GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY
EP2309002A1 (en) * 2009-09-29 2011-04-13 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of colorectal cancer aggressiveness
EP2553118B1 (en) * 2010-03-31 2014-10-15 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
CN103403187A (zh) * 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 结肠直肠癌复发的预后特征
SG192108A1 (en) * 2011-01-25 2013-08-30 Almac Diagnostics Ltd Colon cancer gene expression signatures and methods of use
WO2014041185A2 (en) * 2012-09-17 2014-03-20 Ait Austrian Institute Of Technology Gmbh Colon cancer diagnostic method and means
MX2015006757A (es) * 2012-11-30 2015-11-30 Applied Proteomics Inc Método para la evaluación de la presencia de o riesgo de tumores de colon.
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
DK3743534T3 (da) 2018-01-22 2022-06-20 Liquid Biopsy Res Llc Fremgangsmåde til påvisning af coloncancer og behandlingsovervågning

Also Published As

Publication number Publication date
AU2019209436B2 (en) 2025-06-05
IL276089B1 (en) 2024-03-01
US20190226030A1 (en) 2019-07-25
CN112004945A (zh) 2020-11-27
WO2019144099A1 (en) 2019-07-25
CN112004945B (zh) 2025-02-14
US20250243553A1 (en) 2025-07-31
JP7297770B2 (ja) 2023-06-26
US11414707B2 (en) 2022-08-16
DK3743534T3 (da) 2022-06-20
ES2917629T3 (es) 2022-07-11
SG11202006974WA (en) 2020-08-28
MX2020007771A (es) 2020-09-03
US20230220482A1 (en) 2023-07-13
AU2019209436A1 (en) 2020-08-06
IL276089A (en) 2020-08-31
EP3743534B1 (en) 2022-03-23
EP3743534A1 (en) 2020-12-02
US12305240B2 (en) 2025-05-20
BR112020014737A2 (pt) 2020-12-08
PL3743534T3 (pl) 2022-09-05
JP2021511057A (ja) 2021-05-06
CA3088754A1 (en) 2019-07-25
KR20200113237A (ko) 2020-10-06

Similar Documents

Publication Publication Date Title
IL276089B1 (en) Methods for colon cancer detection and treatment monitoring
JP2021511057A5 (cg-RX-API-DMAC7.html)
US12270081B2 (en) Method for quantification of PD-L1 expression
Huang et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer
WO2020098607A1 (en) A peripheral blood miRNA marker for diagnosis of non-small cell lung cancer
US20090221609A1 (en) Gene Predictors of Response to Metastatic Colorectal Chemotherapy
CN107177669B (zh) 一种胃癌分子标志物hsa_circ_0006633及其应用
US20110256547A1 (en) MicroRNAa (miRNA) AS BIOMARKERS FOR DIAGNOSING DIFFERENT GRADES OF GLIOMAS AND PATHWAYS OF GLIOMA PROGRESSION
JP2017528164A5 (cg-RX-API-DMAC7.html)
EP2655661B1 (en) Methods and means for molecular classification of colorectal cancers
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
ES2686631T3 (es) Determinaciones de cáncer de pulmón utilizando relaciones de miARN
JP2017516501A5 (cg-RX-API-DMAC7.html)
JP7210030B2 (ja) 早期膵がんを診断するための方法およびキット
Tesarova et al. Non-coding transcriptome profiles in clear-cell renal cell carcinoma
TWI854510B (zh) 基於液態活檢的癌症早期篩檢方法
JP2026502347A (ja) 肺がんの検出のための循環バイオマーカーおよびその方法
US20220220562A1 (en) In vitro method for identifying colorectal adenomas or colorectal cancer
Batra et al. EP16. 03-047 Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort
Zheng et al. EP16. 03-046 Tumor Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer
WO2026033435A4 (en) Methods of detecting, diagnosing, classifying and/or monitoring cancers using cell-free dna and kits or devices implementing the same
JP2023152484A (ja) 乳癌の決定および治療の方法
CN116479119A (zh) 胃癌相关环状RNA hsa-circ-0005927标志物的临床应用
JP2024527370A (ja) 膵臓がんに対する循環マイクロrnaシグネチャ
Hagi et al. Supplementary Material for: Molecular Barcode Sequencing for Highly Sensitive Detection of Circulating Tumor DNA in Patients with Esophageal Squamous Cell Carcinoma